All In Biotech

Drug Trial Radar · NCT02081339

Cohort Study of the Clinical Course of Macular Diseases in Japanese

Cohort Study of the Clinical Course of Macular Diseases in Japanese Patients

Last checked: Nov 20, 2026Latest source record: Sep 23, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

1,000

Planned (sponsor's estimate)

Start

Mar 2014

Primary completion

Mar 2022

Study completion Mar 2024

Sponsor

Lead sponsor
Kyoto University, Graduate School of MedicineAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 7, 2014

More drug trials from this sponsor

Design

Study type
Observational
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Recent clinical introduction of anti-vascular endothelial growth factor agents may change the clinical course of macular diseases, including age-related macular degeneration (AMD), polypoidal choroidal vasculopathy (PCV), retinal angiomatous proliferation (RAP), central serous chorioretinopathy (CSC), myopic choroidal neovascularization (CNV), retinal vein occlusion (RVO), diabetic macular edema (DME), and so forth. Patients with such macular diseases are registered and and are followed up for 5 years with appropriate treatment for each patient. By the analysis of the correlation between initial examinations and final visual acuity, factors associated with good visual prognosis will be elucidated.

Conditions

  • Macular Disease

Interventions

  • ranibizumab, aflibercept, pegaptanib, verteporphinDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Initial factors associated with visual prognosis in each macular diseaseTime frame: Five years after the registration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Kyoto University Graduate School of Medicine

    Kyoto, Kyoto, Japan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.